Holen Sie sich die Stockscreener-App
31.50
2.14%
0.715
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$30.79
Offen:
$30.85
24-Stunden-Volumen:
1.05M
Relative Volume:
1.17
Marktkapitalisierung:
$1.45B
Einnahmen:
$203.27M
Nettoeinkommen (Verlust:
$-4.66M
KGV:
-315.05
EPS:
-0.1
Netto-Cashflow:
$3.47M
1W Leistung:
+13.58%
1M Leistung:
+33.43%
6M Leistung:
+202.11%
1J Leistung:
+114.38%
1-Tages-Spanne:
$29.51
$31.53
1-Wochen-Bereich:
$27.50
$34.24
52-Wochen-Spanne:
$9.215
$34.24
Axogen Inc Stock (AXGN) Company Profile
Firmenname
Axogen Inc
Sektor
Branche
Telefon
(386) 462-6817
Adresse
13631 PROGRESS BLVD., ALACHUA, FL
Vergleichen Sie AXGN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AXGN
Axogen Inc
|
31.49 | 1.42B | 203.27M | -4.66M | 3.47M | -0.10 |
|
ABT
Abbott Laboratories
|
121.61 | 212.30B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
93.06 | 139.11B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
351.44 | 135.23B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
100.35 | 129.82B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
83.97 | 48.93B | 5.88B | 1.34B | 799.60M | 2.3489 |
Axogen Inc Stock (AXGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-01 | Eingeleitet | Mizuho | Outperform |
| 2025-03-17 | Eingeleitet | Lake Street | Buy |
| 2024-07-01 | Eingeleitet | Raymond James | Outperform |
| 2022-11-11 | Fortgesetzt | Jefferies | Buy |
| 2022-05-09 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2022-03-11 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2020-10-23 | Eingeleitet | Guggenheim | Buy |
| 2020-06-16 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2020-05-07 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2020-04-02 | Herabstufung | BTIG Research | Buy → Neutral |
| 2019-08-07 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2019-07-12 | Eingeleitet | Canaccord Genuity | Buy |
| 2018-03-02 | Bestätigt | Lake Street | Buy |
| 2018-01-05 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2017-11-30 | Eingeleitet | Jefferies | Buy |
| 2017-11-21 | Bestätigt | Lake Street | Buy |
| 2017-07-31 | Eingeleitet | Leerink Partners | Outperform |
| 2017-06-30 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-03-06 | Eingeleitet | ROTH Capital | Buy |
| 2016-11-22 | Hochstufung | Lake Street | Hold → Buy |
| 2016-11-07 | Bestätigt | Wedbush | Outperform |
| 2016-11-03 | Herabstufung | Lake Street | Buy → Hold |
| 2016-08-04 | Bestätigt | Wedbush | Outperform |
| 2014-05-14 | Eingeleitet | Dawson James | Buy |
| 2013-10-31 | Bestätigt | Ladenburg Thalmann | Buy |
Alle ansehen
Axogen Inc Aktie (AXGN) Neueste Nachrichten
Is Axogen Stock Built to Withstand More Downside? - Trefis
Legal & General Group Plc Purchases 83,175 Shares of AxoGen, Inc. $AXGN - MarketBeat
CFO Hartley Files To Sell 14,387 Of Axogen Inc [AXGN] - TradingView
AxoGen (NASDAQ:AXGN) Trading Down 4.7%What's Next? - MarketBeat
H.C. Wainwright raises AxoGen stock price target to $39 after FDA approval By Investing.com - Investing.com South Africa
H.C. Wainwright raises AxoGen stock price target to $39 after FDA approval - Investing.com Australia
(AXGN) Volatility Zones as Tactical Triggers - news.stocktradersdaily.com
AxoGen approves new CFO compensation and agreement - MSN
Prudential Financial Inc. Trims Stake in AxoGen, Inc. $AXGN - MarketBeat
Axogen (AXGN) Price Target Increased by 18.26% to 34.58 - Nasdaq
AxoGen Secures FDA Approval for Avance Nerve Scaffold - The Globe and Mail
Canaccord Genuity Maintains Axogen (AXGN) Buy Recommendation - Nasdaq
AxoGen Approves New CFO Compensation and Agreement - TipRanks
AXGN: Canaccord Genuity Raises Price Target to $37, Maintains Bu - GuruFocus
AXGN Sees Enhanced Price Target by HC Wainwright & Co. Analyst Y - GuruFocus
Three Stocks Estimated To Be Trading Below Intrinsic Value In December 2025 - simplywall.st
AxoGen (NASDAQ:AXGN) Shares Gap UpHere's What Happened - MarketBeat
AxoGen stock price target raised to $37 from $27 at Canaccord Genuity - Investing.com Nigeria
AxoGen stock price target raised to $37 from $27 at Canaccord Genuity By Investing.com - Investing.com South Africa
AxoGen, Inc. $AXGN Shares Sold by Panagora Asset Management Inc. - MarketBeat
Will Axogen Inc. stock maintain growth storyWeekly Trend Summary & Real-Time Stock Price Movement Reports - Newser
Jefferies Raises Axogen (AXGN) Price Target to $36, Maintains Bu - GuruFocus
Jefferies Maintains Axogen (AXGN) Buy Recommendation - Nasdaq
AXGN: Lake Street Maintains "Buy" Rating and Raises Price Target to $40.00 | AXGN Stock News - GuruFocus
Why Is Axogen Stock Soaring Thursday?Axogen (NASDAQ:AXGN) - Benzinga
AxoGen stock price target raised to $36 from $27 at Raymond James By Investing.com - Investing.com South Africa
AxoGen stock price target raised to $36 from $27 at Raymond James - Investing.com Nigeria
AxoGen stock rises as Mizuho reiterates Outperform on BLA approval By Investing.com - Investing.com Nigeria
Axogen's Avance secures FDA approval for nerve repair - BioWorld MedTech
FDA approves Axogen's nerve repair graft - Reuters
AxoGen stock rises as Mizuho reiterates Outperform on BLA approval - Investing.com
Jefferies raises AxoGen stock price target to $36 on Avance BLA approval - Investing.com Nigeria
Jefferies raises AxoGen stock price target to $36 on Avance BLA approval By Investing.com - Investing.com South Africa
Axogen, Inc. (AXGN) Stock: FDA Approval Boosts Avance as a Leading Nerve Repair Solution - parameter.io
Mizuho Begins Coverage on AxoGen (NASDAQ:AXGN) - MarketBeat
FDA Biologic Approval For AVANCE Might Change The Case For Investing In Axogen (AXGN) - simplywall.st
Axogen stock soars after FDA approval for nerve repair product By Investing.com - Investing.com South Africa
Axogen stock soars after FDA approval for nerve repair product - Investing.com
FDA Approves Axogen's (AXGN) Avance for Nerve Repair - GuruFocus
AXGN stock rises pre-market after FDA approves nerve repair graft - MSN
Why Is AXGN Stock Rising Today? - Stocktwits
Axogen (NASDAQ: AXGN) wins FDA Accelerated Approval for Avance nerve graft, eyes Q2 2026 launch - Stock Titan
Axogen, Inc. Announces FDA Approval of Avance® Biologics License - TradingView
Axogen Says FDA Approved Biologics License Application for Avance; Shares Rise Pre-Bell - marketscreener.com
Citizens reiterates Market Outperform rating on AxoGen stock, citing differentiated products - Investing.com
Will Axogen Inc. stock outperform Nasdaq indexDip Buying & Long-Term Capital Growth Strategies - Newser
Lake Street maintains Axogen (AXGN) buy recommendation - MSN
FDA approves Axogen’s nerve repair scaffold under biologics license By Investing.com - Investing.com Nigeria
Axogen gets FDA OK for Avance’s biologics license application (AXGN:NASDAQ) - Seeking Alpha
AxoGen Inc - Reuters
FDA approves Axogen’s nerve repair scaffold under biologics license - Investing.com India
Finanzdaten der Axogen Inc-Aktie (AXGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.36%
0.37%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):